Amylyx Pharmaceuticals Announces Collaboration with Gubra A/S for Development of Long-Acting GLP-1 Receptor Antagonist
On December 30, 2024, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) revealed a strategic collaboration with Gubra A/S for the development of a potential novel long-acting GLP-1 receptor antagonist. The agreement entails identifying a lead development candidate following a screening period for entry into Investigational New Drug (“IND”)-enabling studies. Once the long-acting GLP-1 receptor antagonist is identified, […]
More Stories
Order of the Sinking Star is Ready to Launch on PlayStation 5 and TV
The creator of Braid and The Witness, Jonathan Blow, is returning with an all-new puzzle video game, Order of the...
Netflix’s Upcoming Drama, All the Truth in My Lies: Release Date, Cast, and More
Excited to know about the upcoming Spanish drama on Netflix, All the Truth in My Lies. If you love watching...
Obsession (2026): Release Date, Cast Members, Trailer, Plot, and More
Be Alert: Spoilers Ahead! Are you also a lover of horror shows and looking for upcoming horror movies and series...
Desire 2026: Release Date, Cast Members, Trailer, Audio, and More
Netflix is expanding its international movie lineup with intense action, thriller, and drama that explore the complexities of human emotions....
AI Assistants Overwhelmingly Cite Third-Party Lists, Not Company Homepages, Study Finds
Artificial intelligence assistants overwhelmingly cite third-party “best-of” and comparison pages rather than companies’ own websites, according to a new study...
How Businesses are Incorporating AI Video Into Sales Processes
Over the last few years, businesses have had to rethink their traditional sales processes. Consumers are more empowered to complete...